CTOs on the Move

Bamboo Therapeutics

www.bambootherapeutics.com

 
Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Bamboo Therapeutics raised $49.5M on 02/12/2016

Similar Companies

Pattern Bioscience

Pattern is building a dream team of scientists and visionaries dedicated to addressing this global problem with faster, smarter diagnostics for more precise treatment.

Revibe Technologies

Revibe Technologies is dedicated to helping children and adults overcome obstacles faced in the classroom and workplace by fusing psychology with technology. School psychologist Rich Brancaccio founded Revibe in 2013 to create a specialized tool to help kids overcome their difficulties by leveling the playing field through technology. Revibe is a wearable that leverages proprietary algorithms to help kids adults combat distraction through gentle vibration reminders.

Pharmagreen Biotech

harmagreen is a company focused on BIOTECH SCIENCES utilizing proprietary technologies and formulations in its state of the art CANNABIS BOTANY CENTER

BioDigital

BioDigital is a New York-based biomedical visualization company that is often referred to as being "Google Earth for the Human Body".

VelosBio

VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.